AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KAUG 46 min read$FTH

Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates

Faeth Therapeutics, Inc. (FTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates — Topline results from the Phase 2 PIK-201 trial in endometrial cancer on track for year-end — — First patient dosed in the Phase 1b/2 PIK-101 trial in HR+ breast cancer — — Comp

Original reporting
SEC EDGAR 8-K
Published Aug 4, 2026, 11:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 4, 2026, 12:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$FTH
Bullish
medium confidence
Mentioned
$FTH
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$FTHBullishMed
01

Why it matters

Traders can update funding runway assumptions from the cash increase and reprice event risk around PIK-201 year-end topline and PIK-101 interim data in 2027.

02

Market read

A balance-sheet reset via $200M PIPE and a first dosing update in PIK-101 provide near-term sentiment support, while the key valuation catalysts remain future topline/interim clinical data.

03

What to watch

The article does not provide interim efficacy results for PIK-101 or detailed endpoints for PIK-201, so the market may discount the timeline without data quality specifics.

Relevance 7/10Novelty 7/10Timing: today’s SEC 8-K, pre-market/market-open context

Background

This SEC Form 8-K (Item 2.02) reports Q2 2026 financial results and operational updates for Faeth Therapeutics’ all-oral PI3K/AKT/mTOR inhibitor combination PIKTOR.

Company-level read

Ticker impact

$FTHBullishMedium confidence
Context

Faeth Therapeutics reported Q2 2026 cash of $186.4M (vs $21.2M at Dec. 31) and outlined PIKTOR trial milestones and PIPE financing.

Expected impact

Likely supportive for sentiment and near-term trading, with follow-through dependent on PIK-201 topline timing and PIK-101 interim safety/efficacy.

Evidence & confidence

Cash jump suggests new financing and longer runway, while first dosing in PIK-101 and ongoing PIK-201 on-track status provide concrete catalysts into 2026-2027.

Market effects

Sector

Adds another data point on PI3K/AKT/mTOR pathway oncology development and ongoing capital formation in clinical-stage biotech.

Regional

No specific regional spillover beyond Nasdaq-listed small-cap biotech sentiment.

Global

Limited direct global read-through; primarily affects US biotech risk appetite and clinical-trial funding expectations.

Counterpoint

What could challenge this read

Higher R&D and G&A alongside a large cash increase may still reflect burn-rate acceleration and execution risk before meaningful efficacy readouts.

Key entities

  • issuer
    Faeth Therapeutics, Inc.

    Clinical-stage oncology company developing PIKTOR (serabelisib plus sapanisertib).

  • product_candidate
    PIKTOR

    Investigational all-oral multi-node inhibitor targeting the PI3K/AKT/mTOR pathway.

  • clinical_program
    PIK-201

    Phase 2 trial in second-line advanced endometrial cancer, topline anticipated in the second half of 2026.

  • clinical_program
    PIK-101

    Phase 1b/2 trial in HR+/HER2- advanced breast cancer, first patient dosed in April 2026, interim data anticipated in 2027.

  • financing
    Sensei Biotherapeutics PIPE financing

    Concurrent $200 million PIPE financing referenced alongside the Sensei Biotherapeutics combination.

Read at source← All news

Related articles

OCT 23
$FTHMedAI 8/10

Faeth Therapeutics: Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib

Faeth Therapeutics (FTH) presented preclinical data at ESMO 2026, showing PIKTOR inhibited tumor growth in breast cancer models, comparable or better than gedatolisib. PIKTOR, in combination with fulvestrant and palbociclib, achieved complete tumor growth inhibition. The company expects topline data from FTH-PIK-201 trial in endometrial cancer by year-end 2026 and interim data from FTH-PIK-101 trial in breast cancer in 2027.

finanznachrichten.de2 min
OCT 23
$FTHMedAI 8/10

Faeth presents preclinical data on PIKTOR in breast cancer

Faeth Therapeutics (FTH) presented preclinical data at the European Society for Medical Oncology Congress 2026, showing its drug PIKTOR inhibited tumor growth in breast cancer mouse models. PIKTOR, a combination of serabelisib and sapanisertib, achieved complete tumor growth inhibition or regression when combined with fulvestrant and palbociclib. The company is conducting Phase 2 trials in endometrial and breast cancer, with data expected by year-end 2026 and 2027, respectively.

investing.com2 min
OCT 7
$FTHMedAI 8/10

Sensei Biotherapeutics Highlights PIKTOR Strategy Ahead of Endometrial Trial Readout

Sensei Biotherapeutics (FTH) presented data supporting its PIKTOR regimen, combining serabelisib and sapanisertib, ahead of an upcoming trial readout. The company reported improved progression-free survival in endometrial cancer patients and highlighted safety and dose-selection data. It also discussed potential market opportunities in breast and endometrial cancer, estimating a $5 billion and $1.5 billion annual market, respectively.

finance.yahoo.com2 min
AUG 17
$FTHMed

Why is Faeth Therapeutics stock surging today?

Faeth Therapeutics (FTH) shares rose 5.8% after the FDA granted Fast Track designation to PIKTOR, an investigational all-oral combo of sapanisertib and serabelisib with paclitaxel for advanced or recurrent endometrial cancer with PI3K/AKT/mTOR pathway alterations. The article cites a $54.50 consensus 12-month target and Phase 2 PIK-201 topline data expected by year-end 2026.

investing.com3 min